Application of Intraoperative Transesophageal Echocardiography Imaging of Vein and CLCVP in Early Prediction and Intervention CSA-AKI

Application of Intraoperative Transesophageal Echocardiography Imaging of Vein and Controlled Low Central Venous Pressure in Early Prediction and Intervention of Acute Renal Injury Associated With Cardiac Surgery

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05682716

Enrollment

137

Registered

2023-01-12

Start date

2022-07-15

Completion date

2022-12-27

Last updated

2023-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury

Keywords

Acute Kidney Injury, Acute Kidney Disease, Postoperative complications of cardiac surgery, Transesophageal echocardiography

Brief summary

The goal of this clinical trial is to learn about in postoperative acute kidney injury in cardiac surgery. The main questions it aims to answer are: * Intraoperative Transesophageal Ultrasound Doppler venous imaging can be used to predict the occurrence of cardiac surgery associated acute kidney injury (CSA-AKI ) in the early stage by observing the changes of renal vein, portal vein and hepatic vein blood flow patterns, calculating the renal vein stasis index and portal vein pulsatility index, and evaluating the degree of venous congestion. * Controlled low central venous pressure (CLCVP) technology can reduce the occurrence of CSA-AKI by reducing venous congestion and increasing renal perfusion pressure. Participants will receive Transesophageal Ultrasound Doppler during cardiac surgery. If the participant is assigned to the intervention group, if the central venous pressure of the participant is ≥ 10mmHg 30 minutes after the end of cardiopulmonary bypass, he will receive nitroglycerin pumped to apply the controlled low central venous pressure (CLCVP) technology; If participants are assigned to the control group, no intervention measures will be taken. The researchers will compare the intervention group with the control group to see the occurrence of AKI and AKD after cardiac surgery.

Interventions

COMBINATION_PRODUCTControlled low central venous pressure (CLCVP) technology

Controlled low central venous pressure (CLCVP) technology: after cardiopulmonary bypass, pumping nitroglycerin (0.2-1 ug/kg \* min) and other methods until the end of surgery to maintain the central venous pressure below 10 mmHg.

DRUGNitroglycerin

nitroglycerin (0.2-1 ug/kg \* min)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients aged above 18 years undergoing coronary artery bypass graft or heart valve surgery under cardiopulmonary bypass.

Exclusion criteria

1. Patients with CKD history, end-stage renal disease and renal transplantation before operation 2. Used nephrotoxic drugs within two weeks before operation 3. Known Renal Artery Stenosis and Renal Malformations 4. There are contraindications for transesophageal ultrasound Doppler evaluation of esophageal space occupying lesions

Design outcomes

Primary

Measure	Time frame	Description
Level of Serum creatinine	Before operation to 90 days after operation	SCR

Secondary

Measure	Time frame	Description
Neutrophil gelatinase associated lipid transporter (NGAL)	Before operation to 2 hours after operation	Neutrophil gelatinase associated lipid transporter
Kidney Injury Molecule-1 (KIM-1)	Before operation to 12 hours after operation	Kidney Injury Molecule-1

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026